Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Bladder Urothelial Carcinoma × Ontruzant × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4 Malignant Solid Neoplasm 1 Esophageal Neoplasms 1 Endometrial Adenocarcinoma 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms, Male 1 Bladder Urothelial Carcinoma 1 Adenocarcinoma Of Esophagus 1

Interventions

trastuzumab biosimilar HLX02 1 Trastuzumab 1 Taxes 1 Radiotherapy 1 Radiation 1 Paclitaxel 1 PF-05280014 1 Ontruzant 1 Ogivri 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed

70 enrolled 10 charts

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡